Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis

Review (25 studies; n=11,403, & 21 regimens) noted continuous treatment with bortezomib (V), lenalidomide and dexamethasone (VRD) had largest survival benefit compared with melphalan and prednisone (MP), while RD and thalidomide + MP also probably considerably increase survival.


Cochrane Database of Systematic Reviews